Correction to: Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents with Autism Spectrum Disorder: Design of Two Phase III Studies (SIGN Trials) (Journal of Autism and Developmental Disorders, (2021), 51, 8, (2959-2972), 10.1007/s10803-020-04709-8)
- Crutel, V.
- Lambert, E.
- Penelaud, P.-F.
- Albarrán Severo, C.
- Fuentes, J.
- Rosier, A.
- Hervás, A.
- Marret, S.
- Oliveira, G.
- Parellada, M.
- Kyaga, S.
- Gouttefangeas, S.
- Bertrand, M.
- Ravel, D.
- Falissard, B.
ISSN: 1573-3432, 0162-3257
Año de publicación: 2021
Volumen: 51
Número: 8
Páginas: 2973
Tipo: Errata